Skip to main content
2025 DC/CSEM Professional Conference Main banner
On-Demand

Science Stream

DCS17 - Critical Periods of Diabetes Risk: early life, puberty & pregnancy

Saturday, November 29, 2025
10:45 - 12:00 Toronto
Location: Constitution Hall

    Speaker(s)

  • Carol Huang, MD PhD

    Associate Professor, Pediatric Endocrinologist
    University of Calgary
    University of Calgary
    Calgary, Alberta, Canada

    Disclosure(s): Novo Nordisk Canada: Advisory Board (Terminated, November 18, 2025)

  • Michael B. Wheeler, PhD

    Professor
    University of Toronto
    Etobicoke, Ontario, Canada

    Disclosure(s): I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

  • VINCENT POITOUT, DVM, PhD (he/him/his)

    Professor of Medicine
    Université de Montréal - CRCHUM
    Université de Montréal
    Montréal, Quebec, Canada

    Disclosure(s): Biodexa: Grant/Research Support (Terminated, December 31, 2024); Canadian Institutes of Health Research (CIHR): Grant/Research Support (Ongoing); Charles River Laboratories: Employment (Ongoing); Diabetes Canada: Grant/Research Support (Ongoing); NIH: Grant/Research Support (Ongoing); NSERC: Grant/Research Support (Ongoing)

    • Moderator(s)

  • FL

    FRANCIS C. LYNN, PhD

    University of British Columbia
    Vancouver, British Columbia, Canada

    Disclosure information not submitted.

Disclosure(s):
Carol Huang, MD PhD: Novo Nordisk Canada: Advisory Board (Terminated, November 18, 2025)
Michael B. Wheeler, n/a: I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
VINCENT POITOUT, DVM, PhD: Biodexa: Grant/Research Support (Terminated, December 31, 2024); Canadian Institutes of Health Research (CIHR): Grant/Research Support (Ongoing); Charles River Laboratories: Employment (Ongoing); Diabetes Canada: Grant/Research Support (Ongoing); NIH: Grant/Research Support (Ongoing); NSERC: Grant/Research Support (Ongoing)
Learning Objectives: This session will:
• Describe how critical periods during the life course impact risk and severity of T1D or T2D.
• Describe how puberty is related to risk of T1D or T2D
• Describe how pregnancy is related to risk of GDM
• Describe how pregnancy is related to risk of T1D or T2D in the offspring
• Highlight the underlying mechanisms of action that link endocrine and metabolic changes during critical life periods to risk and severity of T1D or T2D